Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 24.9 0.36% 0.09
NTLA closed up 0.36 percent on Friday, October 23, 2020, on 44 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical NTLA trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Morning Star Bullish 0.36%
Wide Bands Range Expansion 0.36%
20 DMA Support Bullish 6.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 6.00%
Spinning Top Other 6.00%
Wide Bands Range Expansion 6.00%
Down 3 Days in a Row Weakness 6.00%
Wide Bands Range Expansion 2.26%
Older End-of-Day Gignals for NTLA ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 2 days ago
Down 2 % 2 days ago
Down 1% 2 days ago
10 DMA Resistance 2 days ago
Rose Above Previous Day's High 2 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Biology Immune System Emerging Technologies Molecular Biology Genetics Antitrypsin Deficiency Inborn Errors Of Metabolism Genome Editing Liver Diseases Cas9 Chimeric Antigen Receptor CRISPR Transthyretin Amyloidosis

Is NTLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 27.07
52 Week Low 9.18
Average Volume 892,672
200-Day Moving Average 17.76
50-Day Moving Average 21.72
20-Day Moving Average 23.16
10-Day Moving Average 24.69
Average True Range 1.85
ADX 25.1
+DI 32.40
-DI 21.01
Chandelier Exit (Long, 3 ATRs ) 21.51
Chandelier Exit (Short, 3 ATRs ) 24.37
Upper Bollinger Band 27.52
Lower Bollinger Band 18.80
Percent B (%b) 0.7
BandWidth 37.68
MACD Line 1.01
MACD Signal Line 0.97
MACD Histogram 0.0433
Fundamentals Value
Market Cap 1.46 Billion
Num Shares 58.7 Million
EPS -2.00
Price-to-Earnings (P/E) Ratio -12.43
Price-to-Sales 24.67
Price-to-Book 4.15
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.64
Resistance 3 (R3) 26.57 25.93 26.35
Resistance 2 (R2) 25.93 25.48 25.96 26.25
Resistance 1 (R1) 25.41 25.21 25.09 25.48 26.16
Pivot Point 24.77 24.77 24.61 24.80 24.77
Support 1 (S1) 24.25 24.32 23.93 24.32 23.64
Support 2 (S2) 23.61 24.05 23.64 23.55
Support 3 (S3) 23.09 23.61 23.45
Support 4 (S4) 23.16